William Lee, PhD, Executive Vice President Research, Gilead Sciences
Mack Mitchell, MD, VP Medical Affairs & EVP Health System UTSW; CMO Southwestern HRPN
Howard Jaffe, MD, President and COB of the Gilead Foundation. Former CMO Gilead Sciences
The Amygdala founders have deep and varied expertise in drug development and the addiction space. In addition to our individual experiences, we are all former members of the executive management team that built CV Therapeutics into a FIPCO and developed two first-in-class NCEs approved in the US and EU and achieved guideline status in both territories with current global revenues over $1.6B.
Ivan Diamond, MD, PhD, Chief Scientific Officer and Founder
Peter Strumph, President and Chief Executive Officer and Founder
Aug 1, 2017 - Amygdala Neurosciences Initiates Phase 1b Clinical Study of ANS-6637, the First-In-Class Selective ALDH2 Inhibitor in Development as a Treatment for Substance Use Disorder
Lou Lange, MD, PhD, Executive Chairman and Founder
Feb 16, 2017 - Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences
GS-6637 utilizes a novel pathway for the potential treatment of substance and behavior based addictions
Brent Blackburn, PhD, Chief Development Officer
In addition to Lou Lange (Executive Chairman), Ivan Diamond, and Peter Strumph, the BOD includes:
ANS-6637 is in clinical development as an Opioid Sparing agent and treatment for Smoking Cessation and other substance use disorders
Amygdala Neurosciences is developing ANS-6637, a novel Phase-2 ready, highly selective and reversible ALDH2 inhibitor for the treatment of opioid, smoking, alcohol and cocaine substance use disorders. Based on a published mechanism of action in the brain that prevents pathophysiologic dopamine surge and associated craving without changes to basal dopamine, ANS-6637 has the potential to prevent relapse and the acquisition of drug seeking conditioned response.
In published preclinical studies, ALDH2 inhibition reduced self administration, cue- and drug-primed relapse in alcohol, cocaine, heroin, nicotine, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress.
ANS-6637 is ready for outpatient Phase-2 studies. Over 130 human subjects have been exposed to ANS-6637. In Phase-1, ANS-6637 demonstrated safety and tolerability even during heavy alcohol consumption.
A Biopharmaceutical Company Focused on the Development and Commercialization of First-In-Class Drug Candidates for Addiction Disorders
The Board of Directors
Adrienne MacMillan, Chief Financial Officer and Founder